Three receptors, several different kinds of evidence

A three-receptor diagram is a map of proposed biological interactions. It is not a miniature clinical trial. To read the map well, separate the targets from the experiments used to study them. Structural biology can show how an activated receptor is organised. Cell assays can measure a signalling response. Animal experiments can explore effects in an intact model. Human studies address outcomes in their enrolled participants. Each contributes information that the others cannot simply replace.

The target set discussed here contains GLP-1R, GIPR and GCGR: the GLP-1, GIP and glucagon receptors. The triple-agonist discovery study by Coskun and colleagues investigated a molecule acting at all three. A separate study by Willard and colleagues examined tirzepatide's dual GIP and GLP-1 receptor pharmacology. Reading them together reveals why a receptor count is only the beginning. The balance of activity and the response measured in an assay also shape the description.

This article is a guide to the evidence behind a mechanism map. It does not infer that an additional target guarantees a larger clinical benefit or a preferable safety profile. Instead, it asks what each experimental method can establish and which inference would require another study. Keep that distinction visible when a diagram makes a complex programme look like three simple arrows pointing towards a promised result. The arrows need labels, model systems and measured outcomes before they can support a useful explanation.